Bioreductive activation and drug chaperoning in cobalt pharmaceuticals

Citations Over TimeTop 10% of 2007 papers

Abstract

The potential for cobalt(III) complexes in medicine, as chaperones of bioactive ligands, and to target tumours through bioreductive activation, has been examined over the past 20 years. Despite this, chemical properties such as reduction potential and carrier ligands required for optimal tumour targeting and drug delivery have not been optimised. Here we review the chemistry of cobalt(III) drug design, and recent developments in the understanding of the cellular fate of these drugs.

Related Papers

• → Synthetic strategies, structures and properties of di and polynuclear cobalt complexes with H2salen type Schiff bases and their reduced analogues(2021)24 cited
• → The effects of cobalt additions on soil and herbage cobalt concentrations in some S.E. Scotland pastures(1985)13 cited
• → Organo-Cobalt Compounds(1949)5 cited
• → Heteropolytungstates Containing Cobalt(II) or Cobalt(III)(1976)23 cited
• 철결핍빈혈에서 Cobalt(58Co) 배설율 검사의 진단적 가치(1976)